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373Abstracts
Strategies to control the quality and cost of medication use are
largely dependent on the ability to alter selection of medications.
Previous models of prescribing behavior have focused on physi-
cians. In the hospital setting, clinical pharmacists and formulary
committee members are also key players in medication decision-
making. Differences between physicians, formulary committee
members, and clinical pharmacists have not been compared.
Knowledge of these differences could have importance in pre-
dicting the effectiveness of strategies designed to inﬂuence med-
ication use in this setting. OBJECTIVE: The objective of this
study was to describe and compare the opinions of physicians,
clinical pharmacists, and formulary committee members with
respect to key factors that inﬂuence medication prescribing in
community hospitals. METHODS: Physicians, clinical pharma-
cists, and formulary committee members were solicited to 
participate. A trained interviewer administered a standardized
questionnaire designed to elicit opinions of participants regard-
ing the importance of factors thought to inﬂuence the prescrib-
ing of medications. Responses were described using descriptive
statistics, and differences between the groups were determined
by Post hoc analysis. RESULTS: A total of 150 individuals par-
ticipated in the study. Safety, effectiveness, formulary status, and
restrictions on prescribing were considered highly inﬂuential by
all participants. Physicians rated the availability of drug samples,
and personal experience higher (more inﬂuential on prescribing)
than clinical pharmacists and formulary committee members.
Clinical pharmacists and formulary committee members rated
the inﬂuence of recommendations by clinical pharmacists, 
prescribing guidelines, and cost or cost comparisons higher than
physicians. Factors that were drug-related, or that involved
policy-related programs tended to be more inﬂuential than indi-
rect factors. CONCLUSIONS: Those who seek to implement
programs to alter medication use should recognize and employ
factors that are most inﬂuential in the decision-making process.
Further, it may be important to consider differences that exist
between key participants in the medication use process.
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OBJECTIVE: The concept of e-commerce on pharmaceuticals is
a controversial issue affecting both U.S.A and Europe. This
report will evaluate the beneﬁts and disadvantages of online
pharmacies for consumers, pharmacists, and the pharmaceutical
industry. METHODS: The legal background to online phar-
macies in Europe will be examined in accordance with the 
differential pricing and reimbursement issues of some selected
European countries. The reasons for this phenomenon are going
to be analyzed. The easy access, time saving and privacy are the
main explanations, but what about prices? Is internet an indirect
way of parallel trade in pharmaceuticals? What precautions
should be taken for both patients and companies of e-commerce
in pharmaceuticals? RESULTS: Issues of potential risks to public
health because of handling outside regulated distribution chan-
nels. Additionally, lack of prescription in accordance with arrival
without instructions for proper use or in an incorrect dose might
put the health of the patients in danger. CONCLUSION: The
phenomenon of e-commerce on pharmaceuticals is a “headache”
issue for all the involved parties in the medical world, the doctors
who can’t control their patients medicines, pharmacists who lose
market share, patients who take medicines which in many cases
might cause them side effects because they don’t have the per-
mission of the doctor and last but not least pharmaceutical com-
panies which they can’t control their stocks since patients from
different countries order medicines via internet with lower prices
than they are being sold in their country.
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OBJECTIVES: In Australia, drugs are only publicly subsidised
and listed on the Pharmaceutical Beneﬁts Scheme (PBS) if the
Pharmaceutical Beneﬁts Advisory Committee (PBAC) has deter-
mined that the drug is cost effective. This process is in addition
to the regulatory process including the Australian Drug Evalua-
tion Committee (ADEC). Critics of the current scheme have 
commented that requirements of the PBAC have become more
onerous in recent years and that the listing of important new
drugs is being delayed. We sought to analyse all published rec-
ommendations of the PBAC meetings from December 1999 to
June 2003 to determine if there is a relationship between the date
of a drug’s regulatory approval, its PBAC recommendation and
subsequent listing on the PBS. METHODS: There were 4 dates
associated with each application: ADEC meeting date, PBAC
meeting date, projected PBS listing date (the ﬁrst date an
approved drug could be PBS listed) and actual PBS listing date.
We used a logistic regression model to identify variables associ-
ated with successful PBS listing, including the year of the PBAC
meeting, submission type, form of economic analysis and
requested listing restrictions. A second analysis was performed
with the outcome variable being ‘approval within 5 months of
meeting date’, to overcome any bias against 2003 applications
that had a shorter follow-up period. RESULTS: The analysis
showed ‘Year of PBAC meeting’ was statistically signiﬁcant for
successful PBS listing. The other variables were not statistically
signiﬁcant. Using 1999 as the reference year, the odds ratios were
as follows: 2000 = 0.6889, 2001 = 0.5500, 2002 = 0.3917, 2003
= 0.1000. Using the modiﬁed dependent variable (approval
within 5 months) similar results to the above analysis were pro-
duced—the OR for variable Year remained statistically signiﬁ-
cant. CONCLUSIONS: The analysis of factors associated with
PBS listing showed that there was a signiﬁcant downward trend
over the years in successful applications. This trend did not
appear to be associated with the other factors listed.
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OBJECTIVE: In France, for about 30 years, the level of the con-
sumption of pharmacy strongly increased, which increased the
public health insurance expenditure. Policies, who were applied,
increased the costs of the patients. The physicians were blamed
in those drifts. By knowing that the doctor does not have direct
ﬁnancial proﬁts in the recommendation of the pharmacies, we
try to understand if his implication direct or indirect in the
increase of the level of consumption of medication is founded.
This study examines the factors, which inﬂuence the prescription
of medication of the physicians. METHODS: For the empirical
study we used the national base of the data of the French physi-
cians who were observed during the period from 1981 to 2000.
The variables used are the seniority of the physician, the struc-
